Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 16CNS 3Lymphoid 2Plasma cell 1Other solid neoplasm 1Genitourinary 1Endocrine 1

Conditions

Lymphoma 2570Precursor Cell Lymphoblastic Leukemia-Lymphoma 2086Lymphoma, Non-Hodgkin 2057Leukemia, Lymphocytic, Chronic, B-Cell 1771Lymphoma, Follicular 1651Lymphoma, Large B-Cell, Diffuse 1597Leukemia 1172Hodgkin Disease 1128Lymphoma, Mantle-Cell 1110Burkitt Lymphoma 887Leukemia, Myeloid, Acute 885Lymphoma, B-Cell, Marginal Zone 788Recurrence 779Multiple Myeloma 744Lymphoma, B-Cell 704Myelodysplastic Syndromes 615Neoplasms 494Lymphoma, T-Cell, Cutaneous 479Waldenstrom Macroglobulinemia 470Lymphoma, Large-Cell, Immunoblastic 456Mycosis Fungoides 383Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 382Lymphoma, Large-Cell, Anaplastic 362Sezary Syndrome 321Lymphoma, T-Cell, Peripheral 321Leukemia, Myelogenous, Chronic, BCR-ABL Positive 307Hematologic Neoplasms 299Myeloproliferative Disorders 288Neoplasms, Plasma Cell 270Blast Crisis 261

Interventions

Crizotinib 1BAY 1895344 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Rhabdomyosarcoma, Alveolar × Lymphoid × Clear all
NCT05071209 2026-01-23

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
31 enrolled 14 charts
LymphoidSarcoma

Lymphoma, Sarcoma, Ewing, Rhabdomyosarcoma, Alveolar

NCT01524926 2023-12-11

CREATE

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
582 enrolled
LymphoidPlasma cellSarcoma

Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic, Sarcoma, Clear Cell, Rhabdomyosarcoma, Alveolar, Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡